EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients (EBVER/TMC)
This study has been completed.
Sponsor:
Andreas Arnold
Information provided by (Responsible Party):
Andreas Arnold, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01942005
First received: August 7, 2013
Last updated: December 3, 2014
Last verified: December 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.
| Condition |
|---|
|
Immunosuppression Neoplasm |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection |
Further study details as provided by University Hospital, Basel, Switzerland:
Primary Outcome Measures:
- Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen. [ Time Frame: 7 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [ Time Frame: 7 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blutsample
| Enrollment: | 144 |
| Study Start Date: | January 2010 |
| Study Completion Date: | May 2014 |
| Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
patients who underwent organ transplatation or patients who have a HIV infection
Criteria
Inclusion Criteria:
- patients in an immunosuppressive condition either by immunosuppressants or by HIV infection
Exclusion Criteria:
- written informed consent not given
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01942005
Please refer to this study by its ClinicalTrials.gov identifier: NCT01942005
Locations
| Switzerland | |
| University Hospital Basel, Dermatology | |
| Basel, Basel Stadt, Switzerland, 4031 | |
Sponsors and Collaborators
Andreas Arnold
Investigators
| Principal Investigator: | Andreas Arnold, MD | University Hospital Basel, Dermatology, CH-4031 Basel |
More Information
| Responsible Party: | Andreas Arnold, Dr. med. Andreas Arnold, senior physician, University Hospital, Basel, Switzerland |
| ClinicalTrials.gov Identifier: | NCT01942005 History of Changes |
| Other Study ID Numbers: | 11/10 |
| Study First Received: | August 7, 2013 |
| Last Updated: | December 3, 2014 |
| Health Authority: | Switzerland: Ethikkommission |
ClinicalTrials.gov processed this record on September 27, 2016